Main Content start here
Main Layout
Report Description

Report Description

Forecast Period

2026-2030

Market Size (2024)

USD 1.60 Billion

CAGR (2025-2030)

5.30%

Fastest Growing Segment

Hospitals & Clinics

Largest Market

North America

Market Size (2030)

USD 2.18 Billion

Market Overview

The Global Perinatal Infections Market, valued at USD 1.60 Billion in 2024, is projected to experience a CAGR of 5.30% to reach USD 2.18 Billion by 2030. The Global Perinatal Infections Market focuses on diagnostic and therapeutic solutions for infections caused by viruses or bacteria transmitted from a mother to her fetus during gestation or childbirth. Market expansion is substantially driven by the increasing global prevalence of these infections, alongside rising healthcare expenditure and heightened public awareness concerning maternal and child health. Further growth is supported by continuous technological advancements in diagnostic methodologies and treatment modalities, facilitating earlier detection and more effective interventions.

According to the World Health Organization, in 2022, the global congenital syphilis case rate was 523 per 100,000 live births, highlighting the persistent health burden. A significant challenge that could impede market growth is the scarcity of adequately skilled healthcare professionals capable of providing accurate diagnosis and comprehensive treatment for these complex perinatal conditions.

Key Market Drivers

The Global Perinatal Infections Market is significantly shaped by sustained technological advancements in diagnostics and treatment. Innovations in diagnostic platforms are continuously enhancing the precision and accessibility of early detection for perinatal infections. This includes the development of non-invasive prenatal tests, which allow for screening of complex fetal genetic conditions with reduced risk. For instance, according to Natera, in August 2025, their Fetal Focus test, a noninvasive prenatal test for inherited conditions, was launched, supported by data from a clinical trial that initiated in 2023 and had enrolled approximately 1,300 participants. These diagnostic breakthroughs enable earlier and more accurate identification of infections, facilitating timely intervention and improving outcomes for both mother and child.

Simultaneously, increasing awareness and the implementation of widespread screening programs are crucial in curbing the incidence and severity of perinatal infections. Public health campaigns and government-backed initiatives are vital for educating expectant parents about risks and the importance of early detection. A notable example is the widespread implementation of screening programs: according to the CDC’s MMWR, in August 2024, the Minnesota Department of Health screened 60,115 infants for congenital cytomegalovirus between February 2023 and February 2024. Such initiatives drive demand for diagnostic tools and create opportunities for therapeutic interventions by identifying previously undiagnosed cases. The collective impact of these drivers is evident in global health funding, where, according to the UNICEF Annual Report 2024, during 2024, programmes under Goal Area 1, which includes maternal and child health, incurred total expenses of $2.4 billion globally.


Download Free Sample Report

Key Market Challenges

The scarcity of adequately skilled healthcare professionals capable of providing accurate diagnosis and comprehensive treatment for complex perinatal conditions significantly impedes the growth of the Global Perinatal Infections Market. This shortage directly limits the effective deployment and utilization of innovative diagnostic technologies and therapeutic solutions. When there are insufficient trained personnel, particularly those specializing in infectious diseases, the ability to promptly and accurately identify perinatal infections is compromised. This often leads to delayed treatment initiation, reduced efficacy of available interventions, and poorer maternal and neonatal outcomes.

The lack of specialized expertise creates a bottleneck in the care pathway, preventing new market offerings from reaching their full potential impact. For instance, according to the Infectious Diseases Society of America and the Pediatric Infectious Diseases Society, in 2024, over 80% of counties in the United States lacked any infectious disease expert. This widespread absence directly impacts the capacity to manage the nuances of perinatal infections, thereby slowing the adoption rates and overall expansion of advanced products and services designed for this market.

Key Market Trends

The growing adoption of personalized medicine approaches represents a pivotal trend reshaping the Global Perinatal Infections Market by moving beyond standardized treatments to highly individualized care. This trend emphasizes tailoring diagnostic and therapeutic interventions based on a mother's unique genetic profile, microbial resistance patterns, and immune response, aiming to optimize outcomes for both mother and child. Such customization drives demand for advanced molecular diagnostics capable of identifying specific pathogens and host genetic predispositions with high precision. According to the Personalized Medicine Coalition, the FDA approved 18 new personalized medicines in 2024, constituting 38% of all newly approved therapeutic molecular entities across various treatment areas. Companies are increasingly collaborating in this space; Roche and Janssen Biotech Inc. joined forces in February 2023 to develop personalized and targeted therapies alongside companion diagnostics, signaling a strategic focus on this tailored medical paradigm.

The expansion of maternal immunization strategies is significantly influencing the perinatal infections market by prioritizing preventative measures. This trend involves increasing vaccination rates among pregnant individuals to provide passive immunity to their newborns, thereby reducing the incidence and severity of congenital and neonatal infections. Such strategies directly impact the demand for specific vaccines designed for maternal administration. For instance, the U. S. Food and Drug Administration approved Abrysvo, Pfizer's Respiratory Syncytial Virus Vaccine, in August 2023 for use in pregnant individuals to prevent lower respiratory tract disease and severe LRTD caused by RSV in infants. According to a CDC survey conducted during March 26–April 11, 2024, 33% of eligible pregnant women reported receiving an RSV vaccination, highlighting early adoption of these critical preventative measures.

Segmental Insights

The Hospitals & Clinics segment is experiencing rapid growth in the Global Perinatal Infections Market due to several critical factors. These facilities are equipped with advanced diagnostic tools and infrastructure, enabling accurate and timely detection of perinatal infections in both mothers and newborns. This capability is crucial for implementing prompt treatment and preventing further complications or transmission. Furthermore, hospitals provide a structured environment considered optimal for deliveries and offer specialized care from a diverse team of healthcare professionals. Increased global healthcare expenditure and heightened awareness regarding maternal and child health, alongside supportive government initiatives, also drive patients towards these comprehensive healthcare settings for perinatal infection management.

Regional Insights

North America leads the Global Perinatal Infections Market due to its advanced healthcare infrastructure and substantial healthcare spending. The region's dominance is further driven by an increasing preference for point-of-care testing and a growing demand for personalized medicine. Governments in North America actively support maternal and child health through various initiatives, including screening programs and educational campaigns, which enhance awareness and encourage early diagnosis and treatment of perinatal infections. These concerted efforts, alongside significant investments in advanced diagnostic and therapeutic solutions, contribute to the region's prominent market position.

Recent Developments

  • In October 2025, Australian nano-biotechnology firm Nexsen Limited planned its debut on the Australian Securities Exchange, introducing a novel biosensing platform that provides rapid diagnostic results. The company's initial focus for this technology is a Group B Streptococcus (GBS) Rapid Sensor. This innovative device will enable clinicians to test expectant mothers during labor, delivering results within minutes. Such a breakthrough in real-time detection for GBS, a significant perinatal infection, is poised to transform maternal and neonatal care globally by facilitating timely intervention.

  • In June 2025, Merck announced that its product, ENFLONSIA™ (clesrovimab-cfor), received approval from the U.S. Food and Drug Administration (FDA) for preventing respiratory syncytial virus (RSV) lower respiratory tract disease in neonates and infants. This monoclonal antibody is intended for infants born during or entering their first RSV season. ENFLONSIA offers a standardized dose regardless of weight and is designed to provide rapid and sustained protection for up to five months, covering a typical RSV season. This new product launch provides a significant intervention to help safeguard infants from a prevalent seasonal infection within the perinatal infections market.

  • In April 2025, breakthrough research presented at ESCMID Global 2025 identified interleukin-6 (IL-6) as a promising diagnostic biomarker for the early detection of sepsis. This study specifically evaluated IL-6's diagnostic performance in high-risk patient groups, including neonates, children, and pregnant women. The findings reinforce the potential for companies to develop and widely adopt commercially available testing platforms utilizing IL-6 to significantly improve clinical decision-making. Such advancements would support timely, targeted treatment for sepsis, a life-threatening perinatal infection.

  • In October 2024, scientists identified a four-gene signature detectable in newborns' blood at birth that predicts the development of early-onset sepsis. This breakthrough research, co-funded by the National Institutes of Health's National Institute of Allergy and Infectious Diseases (NIAID), could facilitate earlier treatment for neonatal sepsis. By predicting the condition before symptoms appear, this genetic signature has the potential to guide clinicians in identifying at-risk newborns, thus potentially reducing the need for broad-spectrum antibiotic use. The findings pave the way for future commercial diagnostic tools in the perinatal infections market.

Key Market Players

  • Merck KGaA
  • Beckman Coulter Inc.
  • Bio-Rad Laboratories, Inc
  • Hologic Inc.
  • Gilead Sciences, Inc.
  • Emcure Pharmaceuticals Limited.
  • Cipla Inc.
  • Bausch Health Companies Inc
  • Johnson & Johnson
  • Teva Pharmaceutical Industries Ltd.

By Infection Type

By Treatment

By Diagnosis

By End user

By Region

  • Cytomegalovirus Infection
  • Enterovirus Infection
  • Genital Herpes
  • Gonorrhoea
  • Human Immunodeficiency Virus
  • Listeriosis Lymphocytic Choriomeningitis Virus
  • Rubella
  • Syphilis
  • Varicella
  • Others
  • Antibiotics
  • Antiviral
  • Antiretroviral
  • Others
  • Maternal Test
  • Neonatal Test
  • Others
  • Hospitals & Clinics
  • Ambulatory Care Centers
  • Others
  • North America
  • Europe
  • Asia Pacific
  • South America
  • Middle East & Africa
  • Report Scope:

    In this report, the Global Perinatal Infections Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

    • Perinatal Infections Market, By Infection Type:

    o   Cytomegalovirus Infection

    o   Enterovirus Infection

    o   Genital Herpes

    o   Gonorrhoea

    o   Human Immunodeficiency Virus

    o   Listeriosis Lymphocytic Choriomeningitis Virus

    o   Rubella

    o   Syphilis

    o   Varicella

    o   Others

    • Perinatal Infections Market, By Treatment:

    o   Antibiotics

    o   Antiviral

    o   Antiretroviral

    o   Others

    • Perinatal Infections Market, By Diagnosis:

    o   Maternal Test

    o   Neonatal Test

    o   Others

    • Perinatal Infections Market, By End user:

    o   Hospitals & Clinics

    o   Ambulatory Care Centers

    o   Others

    • Perinatal Infections Market, By Region:

    o   North America

    §  United States

    §  Canada

    §  Mexico

    o   Europe

    §  France

    §  United Kingdom

    §  Italy

    §  Germany

    §  Spain

    o   Asia Pacific

    §  China

    §  India

    §  Japan

    §  Australia

    §  South Korea

    o   South America

    §  Brazil

    §  Argentina

    §  Colombia

    o   Middle East & Africa

    §  South Africa

    §  Saudi Arabia

    §  UAE

    Competitive Landscape

    Company Profiles: Detailed analysis of the major companies presents in the Global Perinatal Infections Market.

    Available Customizations:

    Global Perinatal Infections Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

    Company Information

    • Detailed analysis and profiling of additional market players (up to five).

    Global Perinatal Infections Market is an upcoming report to be released soon. If you wish an early delivery of this report or want to confirm the date of release, please contact us at [email protected]

    Table of content

    Table of content

    1.    Product Overview

    1.1.  Market Definition

    1.2.  Scope of the Market

    1.2.1.  Markets Covered

    1.2.2.  Years Considered for Study

    1.2.3.  Key Market Segmentations

    2.    Research Methodology

    2.1.  Objective of the Study

    2.2.  Baseline Methodology

    2.3.  Key Industry Partners

    2.4.  Major Association and Secondary Sources

    2.5.  Forecasting Methodology

    2.6.  Data Triangulation & Validation

    2.7.  Assumptions and Limitations

    3.    Executive Summary

    3.1.  Overview of the Market

    3.2.  Overview of Key Market Segmentations

    3.3.  Overview of Key Market Players

    3.4.  Overview of Key Regions/Countries

    3.5.  Overview of Market Drivers, Challenges, Trends

    4.    Voice of Customer

    5.    Global Perinatal Infections Market Outlook

    5.1.  Market Size & Forecast

    5.1.1.  By Value

    5.2.  Market Share & Forecast

    5.2.1.  By Infection Type (Cytomegalovirus Infection, Enterovirus Infection, Genital Herpes, Gonorrhoea, Human Immunodeficiency Virus, Listeriosis Lymphocytic Choriomeningitis Virus, Rubella, Syphilis, Varicella, Others)

    5.2.2.  By Treatment (Antibiotics, Antiviral, Antiretroviral, Others)

    5.2.3.  By Diagnosis (Maternal Test, Neonatal Test, Others)

    5.2.4.  By End user (Hospitals & Clinics, Ambulatory Care Centers, Others)

    5.2.5.  By Region

    5.2.6.  By Company (2024)

    5.3.  Market Map

    6.    North America Perinatal Infections Market Outlook

    6.1.  Market Size & Forecast

    6.1.1.  By Value

    6.2.  Market Share & Forecast

    6.2.1.  By Infection Type

    6.2.2.  By Treatment

    6.2.3.  By Diagnosis

    6.2.4.  By End user

    6.2.5.  By Country

    6.3.    North America: Country Analysis

    6.3.1.    United States Perinatal Infections Market Outlook

    6.3.1.1.  Market Size & Forecast

    6.3.1.1.1.  By Value

    6.3.1.2.  Market Share & Forecast

    6.3.1.2.1.  By Infection Type

    6.3.1.2.2.  By Treatment

    6.3.1.2.3.  By Diagnosis

    6.3.1.2.4.  By End user

    6.3.2.    Canada Perinatal Infections Market Outlook

    6.3.2.1.  Market Size & Forecast

    6.3.2.1.1.  By Value

    6.3.2.2.  Market Share & Forecast

    6.3.2.2.1.  By Infection Type

    6.3.2.2.2.  By Treatment

    6.3.2.2.3.  By Diagnosis

    6.3.2.2.4.  By End user

    6.3.3.    Mexico Perinatal Infections Market Outlook

    6.3.3.1.  Market Size & Forecast

    6.3.3.1.1.  By Value

    6.3.3.2.  Market Share & Forecast

    6.3.3.2.1.  By Infection Type

    6.3.3.2.2.  By Treatment

    6.3.3.2.3.  By Diagnosis

    6.3.3.2.4.  By End user

    7.    Europe Perinatal Infections Market Outlook

    7.1.  Market Size & Forecast

    7.1.1.  By Value

    7.2.  Market Share & Forecast

    7.2.1.  By Infection Type

    7.2.2.  By Treatment

    7.2.3.  By Diagnosis

    7.2.4.  By End user

    7.2.5.  By Country

    7.3.    Europe: Country Analysis

    7.3.1.    Germany Perinatal Infections Market Outlook

    7.3.1.1.  Market Size & Forecast

    7.3.1.1.1.  By Value

    7.3.1.2.  Market Share & Forecast

    7.3.1.2.1.  By Infection Type

    7.3.1.2.2.  By Treatment

    7.3.1.2.3.  By Diagnosis

    7.3.1.2.4.  By End user

    7.3.2.    France Perinatal Infections Market Outlook

    7.3.2.1.  Market Size & Forecast

    7.3.2.1.1.  By Value

    7.3.2.2.  Market Share & Forecast

    7.3.2.2.1.  By Infection Type

    7.3.2.2.2.  By Treatment

    7.3.2.2.3.  By Diagnosis

    7.3.2.2.4.  By End user

    7.3.3.    United Kingdom Perinatal Infections Market Outlook

    7.3.3.1.  Market Size & Forecast

    7.3.3.1.1.  By Value

    7.3.3.2.  Market Share & Forecast

    7.3.3.2.1.  By Infection Type

    7.3.3.2.2.  By Treatment

    7.3.3.2.3.  By Diagnosis

    7.3.3.2.4.  By End user

    7.3.4.    Italy Perinatal Infections Market Outlook

    7.3.4.1.  Market Size & Forecast

    7.3.4.1.1.  By Value

    7.3.4.2.  Market Share & Forecast

    7.3.4.2.1.  By Infection Type

    7.3.4.2.2.  By Treatment

    7.3.4.2.3.  By Diagnosis

    7.3.4.2.4.  By End user

    7.3.5.    Spain Perinatal Infections Market Outlook

    7.3.5.1.  Market Size & Forecast

    7.3.5.1.1.  By Value

    7.3.5.2.  Market Share & Forecast

    7.3.5.2.1.  By Infection Type

    7.3.5.2.2.  By Treatment

    7.3.5.2.3.  By Diagnosis

    7.3.5.2.4.  By End user

    8.    Asia Pacific Perinatal Infections Market Outlook

    8.1.  Market Size & Forecast

    8.1.1.  By Value

    8.2.  Market Share & Forecast

    8.2.1.  By Infection Type

    8.2.2.  By Treatment

    8.2.3.  By Diagnosis

    8.2.4.  By End user

    8.2.5.  By Country

    8.3.    Asia Pacific: Country Analysis

    8.3.1.    China Perinatal Infections Market Outlook

    8.3.1.1.  Market Size & Forecast

    8.3.1.1.1.  By Value

    8.3.1.2.  Market Share & Forecast

    8.3.1.2.1.  By Infection Type

    8.3.1.2.2.  By Treatment

    8.3.1.2.3.  By Diagnosis

    8.3.1.2.4.  By End user

    8.3.2.    India Perinatal Infections Market Outlook

    8.3.2.1.  Market Size & Forecast

    8.3.2.1.1.  By Value

    8.3.2.2.  Market Share & Forecast

    8.3.2.2.1.  By Infection Type

    8.3.2.2.2.  By Treatment

    8.3.2.2.3.  By Diagnosis

    8.3.2.2.4.  By End user

    8.3.3.    Japan Perinatal Infections Market Outlook

    8.3.3.1.  Market Size & Forecast

    8.3.3.1.1.  By Value

    8.3.3.2.  Market Share & Forecast

    8.3.3.2.1.  By Infection Type

    8.3.3.2.2.  By Treatment

    8.3.3.2.3.  By Diagnosis

    8.3.3.2.4.  By End user

    8.3.4.    South Korea Perinatal Infections Market Outlook

    8.3.4.1.  Market Size & Forecast

    8.3.4.1.1.  By Value

    8.3.4.2.  Market Share & Forecast

    8.3.4.2.1.  By Infection Type

    8.3.4.2.2.  By Treatment

    8.3.4.2.3.  By Diagnosis

    8.3.4.2.4.  By End user

    8.3.5.    Australia Perinatal Infections Market Outlook

    8.3.5.1.  Market Size & Forecast

    8.3.5.1.1.  By Value

    8.3.5.2.  Market Share & Forecast

    8.3.5.2.1.  By Infection Type

    8.3.5.2.2.  By Treatment

    8.3.5.2.3.  By Diagnosis

    8.3.5.2.4.  By End user

    9.    Middle East & Africa Perinatal Infections Market Outlook

    9.1.  Market Size & Forecast

    9.1.1.  By Value

    9.2.  Market Share & Forecast

    9.2.1.  By Infection Type

    9.2.2.  By Treatment

    9.2.3.  By Diagnosis

    9.2.4.  By End user

    9.2.5.  By Country

    9.3.    Middle East & Africa: Country Analysis

    9.3.1.    Saudi Arabia Perinatal Infections Market Outlook

    9.3.1.1.  Market Size & Forecast

    9.3.1.1.1.  By Value

    9.3.1.2.  Market Share & Forecast

    9.3.1.2.1.  By Infection Type

    9.3.1.2.2.  By Treatment

    9.3.1.2.3.  By Diagnosis

    9.3.1.2.4.  By End user

    9.3.2.    UAE Perinatal Infections Market Outlook

    9.3.2.1.  Market Size & Forecast

    9.3.2.1.1.  By Value

    9.3.2.2.  Market Share & Forecast

    9.3.2.2.1.  By Infection Type

    9.3.2.2.2.  By Treatment

    9.3.2.2.3.  By Diagnosis

    9.3.2.2.4.  By End user

    9.3.3.    South Africa Perinatal Infections Market Outlook

    9.3.3.1.  Market Size & Forecast

    9.3.3.1.1.  By Value

    9.3.3.2.  Market Share & Forecast

    9.3.3.2.1.  By Infection Type

    9.3.3.2.2.  By Treatment

    9.3.3.2.3.  By Diagnosis

    9.3.3.2.4.  By End user

    10.    South America Perinatal Infections Market Outlook

    10.1.  Market Size & Forecast

    10.1.1.  By Value

    10.2.  Market Share & Forecast

    10.2.1.  By Infection Type

    10.2.2.  By Treatment

    10.2.3.  By Diagnosis

    10.2.4.  By End user

    10.2.5.  By Country

    10.3.    South America: Country Analysis

    10.3.1.    Brazil Perinatal Infections Market Outlook

    10.3.1.1.  Market Size & Forecast

    10.3.1.1.1.  By Value

    10.3.1.2.  Market Share & Forecast

    10.3.1.2.1.  By Infection Type

    10.3.1.2.2.  By Treatment

    10.3.1.2.3.  By Diagnosis

    10.3.1.2.4.  By End user

    10.3.2.    Colombia Perinatal Infections Market Outlook

    10.3.2.1.  Market Size & Forecast

    10.3.2.1.1.  By Value

    10.3.2.2.  Market Share & Forecast

    10.3.2.2.1.  By Infection Type

    10.3.2.2.2.  By Treatment

    10.3.2.2.3.  By Diagnosis

    10.3.2.2.4.  By End user

    10.3.3.    Argentina Perinatal Infections Market Outlook

    10.3.3.1.  Market Size & Forecast

    10.3.3.1.1.  By Value

    10.3.3.2.  Market Share & Forecast

    10.3.3.2.1.  By Infection Type

    10.3.3.2.2.  By Treatment

    10.3.3.2.3.  By Diagnosis

    10.3.3.2.4.  By End user

    11.    Market Dynamics

    11.1.  Drivers

    11.2.  Challenges

    12.    Market Trends & Developments

    12.1.  Merger & Acquisition (If Any)

    12.2.  Product Launches (If Any)

    12.3.  Recent Developments

    13.    Global Perinatal Infections Market: SWOT Analysis

    14.    Porter's Five Forces Analysis

    14.1.  Competition in the Industry

    14.2.  Potential of New Entrants

    14.3.  Power of Suppliers

    14.4.  Power of Customers

    14.5.  Threat of Substitute Products

    15.    Competitive Landscape

    15.1.  Merck KGaA

    15.1.1.  Business Overview

    15.1.2.  Products & Services

    15.1.3.  Recent Developments

    15.1.4.  Key Personnel

    15.1.5.  SWOT Analysis

    15.2.  Beckman Coulter Inc.

    15.3.  Bio-Rad Laboratories, Inc

    15.4.  Hologic Inc.

    15.5.  Gilead Sciences, Inc.

    15.6.  Emcure Pharmaceuticals Limited.

    15.7.  Cipla Inc.

    15.8.  Bausch Health Companies Inc

    15.9.  Johnson & Johnson

    15.10.  Teva Pharmaceutical Industries Ltd.

    16.    Strategic Recommendations

    17.    About Us & Disclaimer

    Figures and Tables

    Frequently asked questions

    Frequently asked questions

    The market size of the Global Perinatal Infections Market was estimated to be USD 1.60 Billion in 2024.

    North America is the dominating region in the Global Perinatal Infections Market.

    Hospitals & Clinics segment is the fastest growing segment in the Global Perinatal Infections Market.

    The Global Perinatal Infections Market is expected to grow at 5.30% between 2025 to 2030.

    Related Reports

    We use cookies to deliver the best possible experience on our website. To learn more, visit our Privacy Policy. By continuing to use this site or by closing this box, you consent to our use of cookies. More info.